This site is intended for healthcare professionals

EU recommends change to marketing authorisation for Epclusa in chronic hepatitis C virus infection.- Gilead Sciences

Read time: 1 mins
Published:28th Jun 2020

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Epclusa (sofosbuvir + velpatasvir), from Gilead Sciences in chronic hepatitis C virus (HCV) infection. The CHMP adopted an extension to the indication for Epclusa as follows: Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults patients aged 6 years and older and weighing at least 17 kg. The CHMP also recommended the addition of a new 200/50 mg strength for the film-coated tablets.

Condition: Hepatitis C
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.